Health AI Central
Share:
Peer-Reviewed Publication
Neuro Oncol2026;28(5):1316-1334.May 1, 2026Journal Article

MIF-CD74 signaling drives immune modulation in medulloblastoma.

Benjamin Draper1, Zhen You2, Dean Thompson3, Xu Guo2, Alaide Morcavallo4, Diego Chillon Pino1, Carlos Lorenzo Gido Nery1, Sumana Shrestha1,4, Chantelle E Bowers1, Courtney Himsworth1, Alberto Delaidelli5,6, Bethany Remeniuk7, Sonia Morlando1, Brandon Wade1, Freya Gordon1, Yara Sanchez-Corrales1, Bei Hopkins7, Natalie Monteiro7, Darren Locke7, Miao Liu2, Jacob Torrejon Diaz8, Kevin Greenslade4, Barbara Martins da Costa4, Karen Barker4, Colin Kwok4, Olumide Ogunbiyi1, Anya Fletcher3, Stacey Richardson3, Carlos Custodia9,10,11, Rafael Roque9,10,11, Thomas Jackson1, Regan Barfoot4, Sergi Castellano1, Rebecca M Hill3, Olivier Saulnier12, Thomas S Jacques1,13, Michael D Taylor14,15,16,17, Claudia C Faria9,10,11, Olivier Ayrault8, Poul H Sorensen5, John Anderson1,13, Louis Chesler4, L Frank Huang2, Steven C Clifford3, Laura K Donovan1
1UCL Great Ormond Street Institute of Child Health, London, UK.
2Department of Pediatric and Adolescent Medicine, Department of Biochemistry and Molecular Biology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
3Wolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK.
4Centre for Paediatric Oncology Experimental Medicine, Institute of Cancer Research, Sutton, UK.
5BC Cancer Centre, Vancouver, Canada.
6Department of Pathology, Mass General Brigham, Harvard Medical School, Boston, Massachusetts, USA.
7Akoya Biosciences, Marlborough, Massachusetts, USA.
8Institut Curie, PSL Research University, Université Paris Sud, Université Paris-Saclay, CNRS, Paris, France.
9Gulbenkian Institute for Molecular Medicine (GIMM), Lisboa, Portugal.
10Neurosurgery Department, Hospital de Santa Maria, Unidade Local de Saúde de Santa Maria (ULSSM), Lisboa, Portugal.
11Clínica Universitária de Neurocirurgia, Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal.
12Inserm U1330, Genomics and Development of Childhood Cancers Lab, Institut Curie, PSL University, SIREDO Oncology Center, Paris, France.
13Great Ormond Street Children's Hospital, London, UK.
14Texas Children's Cancer and Hematology Center, Houston, Texas, USA.
15Department of Pediatrics-Hematology/Oncology, Baylor College of Medicine, Houston, Texas, USA.
16Department of Neurosurgery, Baylor College of Medicine, Houston, Texas, USA.
17Department of Neurosurgery, Texas Children's Hospital, Houston, Texas, USA.
PubMed PMC DOI PDF

Abstract

BACKGROUND: Relapsed medulloblastoma remains a significant therapeutic challenge as it is near universally fatal. The tumor microenvironment of medulloblastoma plays a critical role in tumor progression, influencing tumor growth, immune evasion, and therapeutic resistance. We hypothesized that defining tumor-immune interactions in diagnostic and relapsed medulloblastoma may uncover mechanisms of i…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.